Shilpa Medicare launches dissolving oral thin films of Paracetamol
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
The GMP certificate is valid for three years until April 2024.
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
This oxygen is being provided free-of-cost to several state governments across the country to bring immediate relief to over 1 lakh patients on a daily basis
The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Subscribe To Our Newsletter & Stay Updated